Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In an analysis of data from almost 4000 carriers of Lynch syndrome-associated mutations, we found history of gastric cancer to be independently associated with male sex, older age, mutations in MLH1 or MSH2, and with having a first-degree relative with gastric cancer.
|
31319185 |
2020 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
TP53 mutations were highly recurrent (11/14; 79%) in MLH1-positive miGCs and were detected even in two microscopic lesions measuring 1 and 3 mm, respectively.
|
30474112 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We detected the epidermal growth factor receptor L858R, MSH2 R929* and telomerase reverse transcriptase amplification in the lung cancer specimen; CDH1 c.1320+1G>T mutation in the gastric cancer (GC) specimen; and MLH1 c.1896+5G>A germline mutation in the lung and GC specimens by 450 cancer-related gene mutations detection using next-generation sequencing technology.
|
31207149 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Microsatellite instability (MSI) marker MLH1 and Epstein-Barr virus (EBV) marker EBER were examined on 30 cases of Chinese GC by immunohistochemistry and <i>in situ</i> hybridization.
|
30422018 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
One hundred and sixty-five GCs were classified into five subgroups using immunohistochemistry (IHC) and in situ hybridization (ISH) methods, based on a panel of seven markers (MLH1, PMS2, MSH2, MSH6, E-cadherin, P53, and Epstein-Barr virus mRNA).
|
31372044 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The pooled sensitivity, specificity, and AUC of MLH1 promoter methylation in GC with MSI vs. GC with microsatellite stability (MSS) samples were 0.64, 0.96, and 0.90, respectively.
|
29334683 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association Between hMLH1 Promoter Methylation and Risk of Gastric Cancer: A Meta-Analysis.
|
29719511 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Further study could be conducted to verify the impact of MLH1 methylation on GC prognosis.
|
29896277 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
H3K36me3 and H3K4me2 levels were lower in hMLH1 exon 10-11 and exon 16-17 regions in gastric cancer lines when compared with GES-1.
|
28381181 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The MLH1 rs1800734 polymorphism is associated with GC risk.
|
26724419 |
2016 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
CIMP and/or MLH1 methylation status may have a potential to be prognostic biomarkers for patients with gastric cancer.
|
26121593 |
2015 |
Malignant neoplasm of stomach
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Mismatch repair was affected by a mutation of MLH1 in 1 GC and by aberrant methylation of MLH1 in 2 GCs.
|
24510342 |
2015 |
Malignant neoplasm of stomach
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
TP53 mutation, allelic deletion of the APC gene and nuclear staining of β-catenin are frequently detected in the intestinal phenotype of GC, whereas CDH1 gene mutation, microsatellite instability and DNA hypermethylation of MLH1 are common events in the gastric phenotype of GC.
|
26033320 |
2015 |
Malignant neoplasm of stomach
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MLH1 methylation was related to oxaliplatin resistance in gastric cancer patients.
|
24748501 |
2015 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The DNA methylation occurred in promoter regions of both Reprimo and hMLH1 genes depressed the protein expression, and may participate in the occurrence and progression and gastric cancer.
|
26823831 |
2015 |
Malignant neoplasm of stomach
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant DNA methylation of MGMT and hMLH1 genes in prediction of gastric cancer.
|
24938706 |
2014 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aberrant hypermethylation of P16, MGMT, hMLH1 and hMLH2 could be predictive of gastric cancer.
|
23803092 |
2013 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, some of the known clinicopathologic features of MSI+ GC, including older age of onset, ulcerofungating gross morphology, and antral location, are not typical of MSI+ GC without MLH1 methylation.
|
23266441 |
2013 |
Malignant neoplasm of stomach
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
This study revealed that hMLH1 hypermethylation is strongly associated with GC and suggested roles for epigenetic changes in stomach cancer causation in the Kashmir valley.
|
23098428 |
2012 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
A great number of genes with promoter methylation have been observed in gastric cancer (GC), among which p16INK4A (p16), Mut L homologue 1 (MLH1), Epithelial-cadherin (E-cadherin), Runt-related transcription factor 3 (RUNX3), adenomatous polyposis coli (APC), O(6)-methylguanine-DNA methyltransferase (MGMT), Ras association domain family 1A (RASSF1A) and Death-associated protein kinase (DAPK) have been extensively studied.
|
22936446 |
2012 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To explore germline hypermethylation of the tumor suppressor genes MLH1, CDH1 and P16(INK4a) in suspected cases of hereditary gastric cancer (GC).
|
22228973 |
2012 |
Malignant neoplasm of stomach
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
These data imply that relatives of CRC cases with MLH1 methylation may be at increased risk of CRC and stomach cancer and possibly ovarian and liver cancer, suggesting that there may be a heritable factor for CRC and other cancers associated with MLH1 methylation in non-Lynch syndrome CRCs.
|
22144422 |
2012 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Compared with the MLH1 2101CC genotype, the 2101CA genotype was associated with a risk of gastric cancer (OR = 8.42, 95% CI = 1.04-68.06) in males.
|
22136435 |
2011 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hereditary non-polyposis colorectal cancer is the most common known genetic syndrome that predisposes to various types of cancer including gastric cancer and occures mainly due to pathogenic germline mutations in DNA mismatch repair (MMR) genes, such as MLH1, MSH2 and MSH6.
|
21136174 |
2011 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
We verified that the frequency of MSI was similar in familial and sporadic GC settings, demonstrating that this molecular phenotype is not a hallmark of familial GC in contrast to what is verified in HNPCC.
|
20533283 |
2011 |